Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
VXRT 5.70 - hit my pre-market bid of 5.35 and I immediately wrote the $5.50-Oct. 23-Call at .50...right at 10% juice for a week. Fundies are complex but 10%-per-week can cure alotta warts.
Cuomo calls that a "chinguard" and I thank him for the idea...much more comfortable, no...
The study, which was not peer-reviewed, found that four treatments tested — remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon — had “little or no effect" on whether or not patients died within about a month or whether hospitalized patients recovered.
https://www.fox2detroit.com/news/remdesivir-among-4-drugs-with-little-or-no-effect-on-covid-19-survival-who-study-says
CPSS 4.56 - LAS VEGAS, NV, July 21, 2020...today announced earnings of $3.0 million, or $0.13 per diluted share, for its second quarter ended June 30, 2020...Without the charges related to the pandemic, revenues, total operating expenses and pretax income for the second quarter of 2020 would have been $76.8 million, $59.5 million and $17.3 million, respectively.
https://secfilings.nasdaq.com/filingFrameset.asp?FilingID=14281472&RcvdDate=7/22/2020&CoName=CONSUMER%20PORTFOLIO%20SERVICES,%20INC.&FormType=8-K&View=html
Yep, and currently offering a triple-down bid at 4.25...
...in the process of preparing for a phase 2 expansion that will involve building additional proprietary N-95 Particulate Respiratory face mask production lines to further increase capacity. The phase 2 expansion is expected to be operational by late summer 2020...
YooHoo
APT 14.50 - I cancelled this order (and losing interest in the stock) for lack of any update. This company went from chirpchirpchirping a few months ago into utter silence. Also...masks are just plain annoying.
Will anyone still make a bull case for APT in the midst of this utter silence?
CPSS 4.64 - LAS VEGAS, Nevada, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) today announced that it had received on October 7, 2020 a non-binding, unsolicited indication of interest to acquire the Company from Auto Experience Inc. (“AEI”). Other than a three-page May letter from AEI delivered to the Company’s CFO, and rejected at that time, neither management nor the Board of Directors of the Company have had any discussions with AEI regarding a purchase of the Company.
https://finance.yahoo.com/news/consumer-portfolio-acknowledges-receipt-indication-214600989.html
This longtime solid company might also surprise in it's upcoming earnings report due 11/15...
NBIO .064 - Professor researches antibody as possible treatment for COVID-19
http://dailyorange.com/2020/10/professor-researches-antibody-possible-treatment-covid-19/
NBIO .064 - Professor researches antibody as possible treatment for COVID-19
http://dailyorange.com/2020/10/professor-researches-antibody-possible-treatment-covid-19/
VXRT 6.90 - But if a grand jury becomes involved, the SEC usually has to get the US Attorney’s Office interested in the case after going through its own processes.
“They aren’t using the grand jury as a fishing expedition,” Kaplan said.
https://endpts.com/vaxart-was-served-a-grand-jury-subpoena-in-july-over-its-controversial-role-in-ows-funded-preclinical-study/
The SEC probing around places a serious grey cloud over VXRT's pps that won't get cleared up for some time yet, I suspect?
But if a grand jury becomes involved, the SEC usually has to get the US Attorney’s Office interested in the case after going through its own processes.
“They aren’t using the grand jury as a fishing expedition,” Kaplan said.
https://endpts.com/vaxart-was-served-a-grand-jury-subpoena-in-july-over-its-controversial-role-in-ows-funded-preclinical-study/
The SEC probing around places a serious grey cloud over VXRT's pps that won't get cleared up for some time yet, I suspect?
In August 2020, the Enforcement Division of the Commission requested that the Company provide, on a voluntary basis, a variety of documents that broadly pertain to same subject matters of the documents provided to the U.S. Attorney’s Office, and related matters. The Company has voluntarily provided documents requested by the SEC and is cooperating with this informal inquiry.
https://investors.vaxart.com/node/15576/html
I was unaware there was any SEC inquiry...formal or informal? Has this been mentioned previously?
VXRT 7.67 - like to hear comments on this morning's 'hamster study' news...“Our oral vaccine showed that 100% of hamsters receiving two oral doses of vaccine in the study were protected against systemic weight loss, as well as lung weight gain, which is a key indicator of lung damage due to infection,” said Sean Tucker, Ph.D., chief scientific officer, and founder of Vaxart. “Given that the hamster is a great model for assessing severe infection, this study helps to validate our vaccine’s potential to provide potent protection against COVID-19. These results increase our confidence as we move our vaccine candidate into human clinical trials.”
The study evaluated Vaxart’s recombinant adenoviral vaccine, with doses given at 0 and 4 weeks. Animals were challenged with SARS-CoV-2 at week 8. Topline data demonstrated that all unvaccinated animals lost at least 8% of their body weight, and all showed evidence of lung disease as measured by relative weight gain in the lungs. By contrast, all animals vaccinated with two doses of the oral vaccine maintained or gained body weight by the end of the experiment, a statistically significant result (p<0.001). Additionally, these animals were protected against the lung weight gain seen in the unvaccinated animals (p<0.001). For unvaccinated animals, lung weight as a percentage of body weight was approximately twice that of the animals that received two oral doses of the vaccine. The experiment was designed to monitor systemic weight for 5 days before animals were assessed for lung disease. N=8 per group. Hamsters receiving one oral dose had partial protection. Full results from the study will be published when data analysis is complete.
https://finance.yahoo.com/news/vaxart-announces-positive-hamster-challenge-120000161.html
https://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=soxs&insttype=&freq=2&show=&time=20
One could throw 50 darts and not find a scammier chart...
RIGL 2.67 - SOUTH SAN FRANCISCO, Calif., Oct. 9, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced enrollment of the first patients in a multicenter, Phase 2 trial to evaluate the safety of fostamatinib, Rigel's oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of hospitalized COVID-19 patients. The study is sponsored by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), in collaboration with Inova® Health System. Fostamatinib, marketed in the U.S. as TAVALISSE® (fostamatinib disodium hexahydrate) tablets, is approved in the U.S. and Europe as a treatment for adult chronic immune thrombocytopenia (ITP).
https://finance.yahoo.com/news/rigel-announces-first-patients-enrolled-113000920.html
CPSS 4.63 - started buying this longtime-value-stock in the mid-4's this morning with one flip in the bank. Looks like a real solid investment-or-flip here at this pps and after the $6+ offer...a superplay if 'Auto Experience' were to up the offer as you suggest is possible.
NBIO .059 - SAN DIEGO, CA / ACCESSWIRE / October 7, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech" or the "Company") announces today that the Company is in the process of making significant additions to its core team in order to prepare for the initiation of key Phase One clinical trials to study the safety and efficacy of the Company's flagship drug, Pritumumab (PTB), a monoclonal antibody, for the treatment of Brain Cancer.
https://finance.yahoo.com/news/nascent-biotech-announces-key-personnel-120000609.html
The onset of this Phase 1 entails Brain Cancer studies...the separate covid-19 therapeutic & vaccine studies are all bonus to the risk taken here...
NBIO .059 - SAN DIEGO, CA / ACCESSWIRE / October 7, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech" or the "Company") announces today that the Company is in the process of making significant additions to its core team in order to prepare for the initiation of key Phase One clinical trials to study the safety and efficacy of the Company's flagship drug, Pritumumab (PTB), a monoclonal antibody, for the treatment of Brain Cancer.
https://finance.yahoo.com/news/nascent-biotech-announces-key-personnel-120000609.html
APT 16.03 - wade, masks are competitive but also their highest margin. Of concern is the lack of update on thier 'Phase 2' production rampup...without this, will they be able to meet nearterm expectations?
Also I ordered 500 alphaprotech-masks from expressmedical back on 7/3...
Date Ordered: Friday 03 July, 2020
The comments for your order are
Due to high demand, this item is on allocation with an ETA of September. Please call or email if you would still like for this order to be processed.
This has currently digressed into...
Orders at Express Medical Supplies
Sep 9, 2020, 8:36 AM
to me
They will not give us an exact date. Would you like to keep this on order?
IPIX / NBIO - I used 'scammy' more in a sense of the entire penny market.
IPIX announced good news - a pre-IND meeting with the FDA for Brilacidin while NBIO has an onging Phase 1 trial with it's Pritumumab. Being that Pritumumab and Brilacidin are both longshots...I'll take the 'Phase 1' over a 'pre-IND'...and the fact that NBIO also has a corroboration with a major University on a covid pre-clinical does seem to put NBIO in favor over IPIX
And when one contrasts the IPIX-$70M-cap against the NBIO-$5M-cap - NBIO becomes a no-brainer
APT 16.00 - sold half premarket at 16.50 and the other half will get assigned at 15.00.
#1. no update on the Phase 2 expansion (end of Q3) so this is not a positive.
#2. so much yo-yo-volatility here - good chance to get back in lower.
#3. market primed to collapse on Trump-covid news...do Biden & Cris Wallace have it too??
Still like the stock and could very well pop over 20 at anytime...
On that 'shorting' note, likewise after taking several lumps I ceased all shorting and began looking more instead at patiently waiting for extreme dips...of which this morning looks like a potential onset of many many dips...i.e. Trump-covid the trigger for a waaayyyyy overdue broad-market implosion?
Already trimming in pre-market and intend to be extremely lean at the close heading into the weekend...
Well, yes NBIO is a pennystock that has no product revenue. I'm hoping that one day NBIO will graduate up to using the bigleague-touts such as H C Wainright, RBC Capital et al....those that tout for the big bucks?
and while scammy IPIX still trades at an approx. $70M cap...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=154100596
yep and most of us watched ADIL yesterday spike all over the place on complete nonsense.
In addition to Gavins Felicity's main focus on NBIO's ongoing Phase 1 brain-cancer trial, NBIO has an ongoing corroboration with Syracuse Univ on a pre-clinical covid study in mice (updates any day now)...
“Our hope is that when we treat cells with Pritumumab, it will bind to CSV, and effectively block the SARS2 virus from entering the cell,” says Patteson. “An antibody that could block the entry of SARS2 into the cell could be a monumental step in the fight against COVID-19.”
Patteson will test the hypothesis on mouse embryo fibroblast cells and lung airway epithelial cells to determine if the antibody will block the uptake of SARS2. Using a cell in which vimentin has been knocked out, the results will provide an important control of Pritumumab effects.
https://www.nascentbiotech.com/nascent-biotech-announces-collaboration-with-syracuse-university-advancing-covid-19-research/
https://experts.syr.edu/en/clippings/us-nascent-biotech-syracuse-university-to-develop-covid-19-treatm
Unreal how this legitimate-potential-6 o'clock-newsmaker trades at .065 cents and approx. $5M cap.
NBIO .065 - bullish writeup at biopharmajournal...
By Gavins Felicity -September 29, 2020
Nascent Biotech Inc. (OTCMKTS:NBIO) is a clinical stage biopharmaceutical company with a number of potential drivers and catalysts in play. Today, we take a look at recent analysis and company-specific factors, as well as the macro context, to provide a detailed examination of the stock and its prospects.
https://biopharmajournal.com/2020/09/29/why-nascent-biotech-inc-otcmktsnbio-is-worth-a-close-look
NBIO .065 - bullish writeup at biopharmajournal...
By Gavins Felicity -September 29, 2020
Nascent Biotech Inc. (OTCMKTS:NBIO) is a clinical stage biopharmaceutical company with a number of potential drivers and catalysts in play. Today, we take a look at recent analysis and company-specific factors, as well as the macro context, to provide a detailed examination of the stock and its prospects.
https://biopharmajournal.com/2020/09/29/why-nascent-biotech-inc-otcmktsnbio-is-worth-a-close-look
3 cantankerous gringos...put on show...stop! If they ever make a movie of this first debate it should be titled, "The Three Viejos (not amigos)"
ok throw a pie in my face...chortling is due
ADIL - I was happy to bag a dime. I often think of '10-bagger' in situations like that - how he used to bail immediately, no questions asked, when he discovered even the slightest of bogus surprises...
APT 14.90 - showing strength today...still anticipating a Phase-2-expansion update any minute now 'end of Q3' and upon re-reading the share buyback pr posted on 9/22, I'm also anticipating blowout guidance in addition to a blowout quarter:
Lloyd Hoffman, President and Chief Executive Officer of Alpha Pro Tech, commented, “Our record revenue growth and cash flow generation through the first six months of 2020, in conjunction with the expectation of strong operating results for the remainder of this year based on continued high demand for our products driven largely by the COVID-19 pandemic, facilitated this decision by our Board of Directors. We believe that re-activating and expanding our share repurchase program at this time will deliver value to our shareholders.”
https://finance.yahoo.com/news/alpha-pro-tech-ltd-announces-130000662.html
The formal FDA report shows an "Azure Biotech Inc." in Houston as the official U.S. distributor.
https://www.fda.gov/media/139792/download#:~:text=The%20Assure%20COVID%2D19%20IgG,EDTA)%20and%20fingerstick%20whole%20blood.
Re-reading the wording in this morning's ADIL press release is a bit disingenuous, I believe? I'm out...
ADIL 1.95 - the formal FDA report shows an "Azure Biotech Inc." in Houston as the official U.S. distributor.
https://www.fda.gov/media/139792/download#:~:text=The%20Assure%20COVID%2D19%20IgG,EDTA)%20and%20fingerstick%20whole%20blood.
Re-reading the wording in this morning's ADIL press release is a bit disingenuous, I believe? I'm out...
ADIL 1.95 - the formal FDA report shows an "Azure Biotech Inc." in Houston as the official U.S. distributor.
https://www.fda.gov/media/139792/download#:~:text=The%20Assure%20COVID%2D19%20IgG,EDTA)%20and%20fingerstick%20whole%20blood.
Re-reading the wording in the ADIL press release is a bit disingenuous, I believe? I'm out...
ADIL 1.85 - Granted First Ever FDA Emergency Use Authorization for Use with Fingerstick Blood Samples
https://finance.yahoo.com/news/adial-pharmaceuticals-announces-covid-19-133000140.html
Surprised ADIL not getting more of a spike?
Trump Announces Plan to Ship 150 Million Rapid Coronavirus Tests
Governors of both parties welcomed the plan, but some health experts noted limitations of the kits made by Abbott Laboratories.
https://www.nytimes.com/2020/09/28/health/trump-coronavirus-testing-rapid.html
Maybe afterhours or premarket if ADIL makes the 6 o'clock news
ADIL - Surprised this one not getting more of a spike?
Trump Announces Plan to Ship 150 Million Rapid Coronavirus Tests
Governors of both parties welcomed the plan, but some health experts noted limitations of the kits made by Abbott Laboratories.
https://www.nytimes.com/2020/09/28/health/trump-coronavirus-testing-rapid.html
Maybe afterhours or premarket if ADIL makes the 6 o'clock news
Surprised this one not getting more of a spike?
Trump Announces Plan to Ship 150 Million Rapid Coronavirus Tests
Governors of both parties welcomed the plan, but some health experts noted limitations of the kits made by Abbott Laboratories.
https://www.nytimes.com/2020/09/28/health/trump-coronavirus-testing-rapid.html
Maybe afterhours or premarket if ADIL makes the 6 o'clock news
ADIL 1.84 - nice catch, joined you here...Granted First Ever FDA Emergency Use Authorization for Use with Fingerstick Blood Samples
https://finance.yahoo.com/news/adial-pharmaceuticals-announces-covid-19-133000140.html
Still researching ADIL but at first glance it looks like a decent investment without any covid "First Ever" test kit...
I see no RLFTF SEC-filings therefore not compliant. My opinion is one of:
As a retail investor, I'm surrendering an over-abundance of leverage to these public-stock-managements - even those that are SEC-compliant. And being that there are 1000's of SEC-compliant stocks to choose from, why would I go and surrender ALL leverage to a non-filer...might as well go play the Big-6 wheel in Vegas imo?
INO 12.12 - haven't had any interest here in a more than a month...
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157266808
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157516130
Still playing ALT, VXRT (both w/excellent premium action), ABUS, (waiting to re-sell $5call-or-higher-premiums on any spike) and NBIO (WOW!...the potential in this pennystock...SHEESH) in the covid sector.